The abstract is read at the publisher; the summary is JClub's.
Daratumumab monotherapy in high-risk smoldering multiple myeloma is linked to a significant progression-free survival benefit versus observation, with HR 0.49 (95% CI, 0.36 to 0.67; P < .001).
- Why it matters: Risk stratification is critical because only high-risk SMM patients face a ≥50% progression risk within 2 years, yet overtreatment and unclear overall survival effects remain concerns.
- What they did: The AQUILA randomized phase III trial compared daratumumab monotherapy with observation in high-risk SMM, assessing progression-free survival and overall survival using hazard ratios and confidence intervals.
- The result: Early treatment also showed a trend toward improved overall survival (HR 0.52; 95% CI, 0.27 to 0.98) but with inconclusive OS benefit, supporting risk-adapted, patient-centered management.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.